Eli Lilly SWOT and PESTLE Analysis

Strength

1. Vast geographic spread across major markets: Eli Lilly, a global company with its heart in the USA, has its footprints across UK, Germany, France, Spain, Italy, Brazil, South Asia, Middle East and North Asia- Pacific. Lilly international is responsible for operations across the aforementioned hubs. It delivers innovative medicines to more than 80% people around the world. This sort of geographic presence provides Eli Lilly the much-needed footprints in the most significant target markets across the globe. It manufactures and distribute its products through facilities in the United States and 8 other countries. Its products are sold in approximately 120 countries. The company plans to launch many new drugs in 2022 such as tirazepiide for Type 2 diabetes and donanemab for Alzheimer's disease, and constituting medicines in therapeutic areas such as oncology, diabetes and autoimmune disease - that shall help them foster a steady share of market growth globally.

2. Massive market share in its industry: Eli Lilly enjoyed a strong market share over the years. It commands a stronger hold over its competitors for both human pharmaceutical and animal health products owing to their effectiveness, safety and ease of use, price and demonstrated cost effectiveness, marketing effectiveness, and extent and quality of research and development for new products and processes. An improvement of approximately 32.46% in the market share of Eli Lilly’s Animal Health segment was observed, buoyed by a strong revenue growth of 33.2%. An increase of 9.35% in the market share of Cardio-vascular segment was also observed. Additionally, related growth in other segments like Endocrinology and Neurosciences were also perceived. The company over the past two years has successfully launched numerous products in multiple countries and therapeutic areas, resulting in strong product market shares.

The remaining section under "Strength" is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

This section is available only in the 'Complete Report' on purchase.

Political

This section is available only in the 'Complete Report' on purchase.

Economic

This section is available only in the 'Complete Report' on purchase.

Social

This section is available only in the 'Complete Report' on purchase.

Technological

This section is available only in the 'Complete Report' on purchase.

Legal

This section is available only in the 'Complete Report' on purchase.

Environmental

1. Prioritizing environmental sustainability across operations: In the face of competitive and research based pharmaceutical industry, Eli Lilly thrives to make high quality medicines responsibly. The aim to operate in a manner that is safe, minimizes their natural resource consumption and lessens their impact on the environment. Eli Lilly encourages 'pool bikes' that employees can use to travel to work and has also created a central car sharing website for staff, alongside its offer of shuttle services. All this is done in lieu of reduction of carbon emissions. 9.6% of the electricity Lilly purchased in 2021 came from renewable sources. The sites in Alcobendas, Spain, Kinsale, Ireland, and Bracknell, United Kingdom, receive a significant amount of this renewable electricity through their utility providers. Compared to 2020, they used 2.9 percent less energy and produced 9 percent fewer total greenhouse gas emissions. Lilly estimates that they were able to reuse 97.7 percent of plastic waste for productive purposes (reuse/recycle/waste-to-energy), primarily fueled by recycling plastics from its manufacturing techniques and incoming packaging material. 88% of the plastic trash was recycled or used again. The established aquatic exposure programme limits were fully met by all Lilly manufacturing sites in 2021. Furthermore, all of its sites attained wastewater discharges that were less than 10% of the PNEC-based limits set for pharmaceutical active ingredient.